Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation

Eliem Therapeutics, Inc. (ELYM) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/20/2023 8-K Quarterly results
05/19/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/11/2023 8-K Quarterly results
Docs: "Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, UK, -- – May 11, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023. “We were excited to share our initial preclinical ...",
"Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation"
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/06/2023 8-K Quarterly results
Docs: "Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, UK, -- – March 6, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. “We are excited to advance our Kv7 program forward with ETX-123 as..."
01/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/20/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
Docs: "Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, UK, -- – November 14, 2022 – Eliem Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended September 30, 2022. &#x2...",
"2 NO FOOD EFFECT3 ETX-155"
10/05/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/25/2022 8-K Other Events  Interactive Data
03/29/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Presentation"
03/07/2022 8-K Quarterly results
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/18/2022 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/22/2021 8-K Other Events  Interactive Data
11/08/2021 8-K Investor presentation, Quarterly results
Docs: "Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive disorder and perimenopausal depression clinical trials Continued to enroll ETX-810’s two Phase 2a chronic pain clinical trials, with topline data anticipated in the first half of 2022 On track to progress Kv7.2/3 channel opener program into Investigational New Drug -enabling studies in the first half of 2022 SEATTLE and CAMBRIDGE, UK, -- – November 8, 2021 – Eliem Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in...",
"1H 2023 1H 2023 2024 SAGE-217"
09/13/2021 8-K Quarterly results
08/12/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 12, 2021 ELIEM THERAPEUTICS, INC. Delaware 001-40708 83-2273741 23515 NE Novelty Hill Road, Suite B221 #125 Redmond, WA 98053 276-2300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuan...",
"Amended and Restated Certificate of Incorporation of Eliem Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy